The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.

Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Factors contributing to the ramifications of this disease as it stands include the socio-economic: overweight and obesity ...

A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...